Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsElgaher, Walid A M
Sharma, Kamal K
Hartmann, Rolf W
MetadataShow full item record
AbstractWe are concerned with the development of novel anti-infectives with dual antibacterial and antiretroviral activities for MRSA/HIV-1 co-infection. To achieve this goal, we exploited for the first time the mechanistic function similarity between the bacterial RNA polymerase (RNAP) "switch region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site. Starting from our previously discovered RNAP inhibitors, we managed to develop potent RT inhibitors effective against several resistant HIV-1 strains with maintained or enhanced RNAP inhibitory properties following a structure-based design approach. A quantitative structure-activity relationship (QSAR) analysis revealed distinct molecular features necessary for RT inhibition. Furthermore, mode of action (MoA) studies revealed that these compounds inhibit RT noncompetitively, through a new mechanism via closing of the RT clamp. In addition, the novel RNAP/RT inhibitors are characterized by a potent antibacterial activity against S. aureus and in cellulo antiretroviral activity against NNRTI-resistant strains. In HeLa and HEK 293 cells, the compounds showed only marginal cytotoxicity.
CitationDiscovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors. 2016: J. Med. Chem.
AffiliationHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
JournalJournal of medicinal chemistry
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: structure-based optimization of a virtual screening hit.
- Authors: Sahner JH, Groh M, Negri M, Haupenthal J, Hartmann RW
- Issue date: 2013 Jul
- A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus.
- Authors: Arhin F, Bélanger O, Ciblat S, Dehbi M, Delorme D, Dietrich E, Dixit D, Lafontaine Y, Lehoux D, Liu J, McKay GA, Moeck G, Reddy R, Rose Y, Srikumar R, Tanaka KS, Williams DM, Gros P, Pelletier J, Parr TR Jr, Far AR
- Issue date: 2006 Sep 1
- Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.
- Authors: Hinsberger S, Hüsecken K, Groh M, Negri M, Haupenthal J, Hartmann RW
- Issue date: 2013 Nov 14
- Binding mode characterization of novel RNA polymerase inhibitors using a combined biochemical and NMR approach.
- Authors: Fruth M, Plaza A, Hinsberger S, Sahner JH, Haupenthal J, Bischoff M, Jansen R, Müller R, Hartmann RW
- Issue date: 2014 Nov 21
- Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.
- Authors: Milton J, Slater MJ, Bird AJ, Spinks D, Scott G, Price CE, Downing S, Green DV, Madar S, Bethell R, Stammers DK
- Issue date: 1998 Oct 6